XOMA

Historical price data

XOMA Royalty Corporation has strategically transformed from a traditional drug discovery company into a specialized biotech royalty aggregator, acquiring future economic rights to milestone and royalty payments from partnered therapeutic assets. Its mission is to provide non-dilutive, non-recourse capital to biotech innovators, building a diversified portfolio of over 120 assets to mitigate binary risk while participating in the upside of drug development. Key achievements include securing a $140 million financing facility backed by its VABYSMO® royalties and building a portfolio with its first FDA-approved asset, VABYSMO, now generating revenue. The strategy focuses on leveraging scientific diligence to acquire rights to pre-commercial assets with blockbuster potential, operated by well-capitalized partners, under a capital-efficient corporate structure.

A scientific and financial diligence platform leveraging deep antibody and biotech expertise to evaluate and acquire economic rights to future milestone and royalty payments from partnered therapeutic assets, transforming clinical data into a structured financial portfolio.

XOMA competes with large royalty acquirers like Royalty Pharma, which focus on late-stage assets, and other financial funds. Its differentiation is its specialized focus on the pre-commercial stage and its deep biotech expertise for diligence, though competition in this niche is growing as alternative biotech financing gains popularity.